Issue 25 - October 2009


Details
0
0
0
s2sdefault
powered by social2s
Author: D. Célier (ASN, France)

In March 2009, ASN was requested by the French Agency for the Safety of Health Products (AFSSAPS, the French competent authority for biomedical research), for advice about a proposed clinical trial intended to evaluate a PET tracer to diagnose Alzheimer's disease (AD). This test involves not only the participation of AD patients, but also of healthy volunteers, all aged 60 years or over. The protocol involves 2 PET-CT examinations, issuing a total effective dose of 18 mSv (F-18 + CT).

  1. Analyse of a reference dosimetry error in electron therapy in Switzerland